"
Team:Imperial College London
From 2009.igem.org
| Line 7: | Line 7: | ||
Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature. | Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature. | ||
| - | The <i>E.ncapsulator</i> provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments. This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in <!--the sphere of--> | + | The <i>E.ncapsulator</i> provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments. This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in manufacturing. |
| + | <!--the sphere of--> | ||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 10:03, 18 September 2009
For iGEM 2009 the Imperial College London team present to you The E.ncapsulator: A versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the gut.
Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature.
The E.ncapsulator provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments. This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in manufacturing.
To find out more about our project, and to learn about each module, click below:
